A practical approach to lipid management in the elderly
Cardiovascular disease (CVD) increases in a curvilinear fashion after 65 years in men and 75 years in women and the majority of all cardiovascular events occur in individuals older then 65 years. There are notable differences in the clinical assessment of hyperlipidaemia, cardiovascular risk estimation as well as the safety and tolerability profiles in the elderly compared to younger individuals. Clinical trial data have now demonstrated the benefits of statin treatment in the elderly in both the primary and secondary prevention settings. There is however limited data for individuals older than 80 years. Little data is available on other lipid modifying medication in the elderly. With continuing increases in average life expectancy, preventive efforts will become increasingly important for preventing morbidity, improving quality of life, and reducing healthcare expenditures for older persons. This emphasizes the importance of clinical decisionmaking and weighing up the risks and benefits of treatment.
Key wordsLipid management elderly cardiovascular disease
low density lipoprotein cholesterol
high density lipoprotein
alanine amino transferase
aspartate amino transferase
Unable to display preview. Download preview PDF.
- 1.World Health Organization. Top 10 causes of death [Fact sheet N°310]; updated October 2008 [cited January 2010] Available from: http://www.who.int/mediacentre/factsheets/fs310/en/index.html
- 8.Corti MC, Guralnik JM, Salive ME et al. Clarifying the direct relationship between total cholesterol and death from coronary heart disease in older persons. Ann Inter Med 1997;126:753–760Google Scholar
- 12.Contois JH, McConnell JP, Sethi AA, et al; AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009;55:407–419CrossRefPubMedGoogle Scholar
- 15.Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002;106:3143–3421Google Scholar
- 16.British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91Suppl 5:v1–52Google Scholar
- 19.Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389Google Scholar
- 36.Williams MA, Fleg JL, Ades PA, et al; American Heart Association Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Secondary prevention of coronary heart disease in the elderly (with an emphasis on patients ≥ 75 years of age): An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002;105:1735–1743CrossRefPubMedGoogle Scholar
- 47.Kamal-Bahl S, Burke T, Watson D, Wentworth C, Ma L. Dosage and titration patterns of extended release niacin in clinical practice. Circulation 2006; 113:e814. American Heart Association 7th Scientific Forum of Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington DC, 2006CrossRefGoogle Scholar